FedCircuitBlog

This morning, the Federal Circuit released five nonprecedential opinions. Three opinions address appeals from patent cases—two from the Patent Trial and Appeal Board and one from the District of Delaware. The additional two opinions address decisions of the Merit Systems Protection Board. Here are the introductions to the opinions.

• Inventor Group Wants To Halt All New PTAB Reviews – U.S. Inventor has filed an injunction request seeking to bar the PTAB from instituting any new patent reviews. However, unlike several tech companies who want to diminish the authority of the USPTO director to deny institution, U.S. Inventor hopes to enhance it.
• Biogen’s Patent Loss Spotlights Need to Stress Invention Novelty – The Federal Circuit’s recent decision emphasizes the need for patent applicants, particularly when seeking to patent biological drug products, to distinguish their inventions from those previously introduced to the public.
• Federal Circuit: Patent Directed to Physician to Patient Communication System Abstract, Invalid – The Federal Circuit issued an opinion earlier this month, which addressed both Section 101 patent eligibility and recusal under 28 U.S.C. § 455(a).

Here’s the latest.

This morning the Federal Circuit issued five nonprecedential opinions: two in patent cases, one in a vaccine case, one in a veterans case, and one in a case appealed from the Merit Systems Protection Board. Additionally, the Federal Circuit issued three Rule 36 judgments. Here are the introductions to the opinions and a list of the Rule 36 judgments.